Open AccessPOINT-COUNTERPOINT: Oncology Congress Debate: Should Initial Chemotherapy for Ovarian Cancer Include Bevacizumab? Yes: Bradley Monk, MD; No: William P. McGuire, MD
Author(s) -
Rabiya S. Tuma
Publication year - 2011
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000393680.30811.3c
Subject(s) - counterpoint , bevacizumab , oncology , medicine , ovarian cancer , chemotherapy , cancer , psychology , pedagogy